Hoang-Minh, Lan B., Siebzehnrubl, Florian A.  ORCID: https://orcid.org/0000-0001-8411-8775, Yang, Changlin, Suzuki-Hatano, Silveli, Dajac, Kyle, Loche, Tyler, Andrews, Nicholas, Massari, Michael Schmoll, Patel, Jaimin, Amin, Krisha, Vuong, Alvin, Jimenez Pascual, Ana, Kubilis, Paul, Garrett, Timothy J., Moneypenny, Craig, Pacak, Christina A., Huang, Jianping, Sayour, Elias J., Mitchell, Duane A., Sarkisian, Matthew R., Reynolds, Brent . and Deleyrolle, Loic P.
2018.
Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma.
EMBO Journal
37
(23)
, e98772.
10.15252/embj.201798772
|
Preview |
PDF
- Accepted Post-Print Version
Download (440kB) | Preview |
Preview |
PDF (Supplementary Information)
- Accepted Post-Print Version
Download (2MB) | Preview |
Abstract
Metabolic reprogramming has been described in rapidly growing tumors, which are thought to mostly contain fast‐cycling cells (FCCs) that have impaired mitochondrial function and rely on aerobic glycolysis. Here, we characterize the metabolic landscape of glioblastoma (GBM) and explore metabolic specificities as targetable vulnerabilities. Our studies highlight the metabolic heterogeneity in GBM, in which FCCs harness aerobic glycolysis, and slow‐cycling cells (SCCs) preferentially utilize mitochondrial oxidative phosphorylation for their functions. SCCs display enhanced invasion and chemoresistance, suggesting their important role in tumor recurrence. SCCs also demonstrate increased lipid contents that are specifically metabolized under glucose‐deprived conditions. Fatty acid transport in SCCs is targetable by pharmacological inhibition or genomic deletion of FABP7, both of which sensitize SCCs to metabolic stress. Furthermore, FABP7 inhibition, whether alone or in combination with glycolysis inhibition, leads to overall increased survival. Our studies reveal the existence of GBM cell subpopulations with distinct metabolic requirements and suggest that FABP7 is central to lipid metabolism in SCCs and that targeting FABP7‐related metabolic pathways is a viable therapeutic strategy.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Biosciences European Cancer Stem Cell Research Institute (ECSCRI) |
| Publisher: | EMBO Press |
| ISSN: | 0261-4189 |
| Date of First Compliant Deposit: | 18 October 2018 |
| Date of Acceptance: | 24 August 2018 |
| Last Modified: | 07 Nov 2024 11:00 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/115991 |
Citation Data
Cited 68 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Dimensions
Dimensions
Cardiff University Information Services